NeuroVectis
Autologous Tissue-Engineered Therapy for Parkinson’s Disease
Company Overview
Snapshot
Founded in January 2026, NeuroVectis operates with 1–10 employees. The company is a planned Matricelf subsidiary focused on developing a regenerative therapy for Parkinson’s disease and Parkinsonism. In February 2026, Matricelf announced the establishment of NeuroVectis as a spin-off to develop living brain implants.
Business overview
NeuroVectis is a planned subsidiary of Matricelf, dedicated to advancing regenerative therapies for Parkinson’s disease and Parkinsonism. The company's core technology involves an autologous tissue-engineered therapy that utilizes patient-derived cells, extracellular matrix, hydrogel, and engineered neural tissue. This approach aims to create a living implant designed to restore dopamine production and support brain-tissue repair, moving beyond symptomatic management. NeuroVectis operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Biomaterials & Tissue Engineering.
Strategic signal
In February 2026, Matricelf announced the establishment of NeuroVectis as a spin-off company, dedicated to developing living brain implants for Parkinson's disease. This strategic move signals a focused effort to accelerate the development and commercialization of a regenerative medical solution, indicating a significant commitment to addressing a critical unmet medical need with advanced biomaterials and tissue engineering.
Company Intelligence Q&A
- What is NeuroVectis's primary focus?
- NeuroVectis is focused on developing an autologous tissue-engineered therapy for Parkinson’s disease and Parkinsonism, utilizing patient-derived cells and engineered neural tissue to restore dopamine production and support brain-tissue repair.
- When was NeuroVectis founded?
- NeuroVectis was founded in January 2026.
- What is the relationship between NeuroVectis and Matricelf?
- NeuroVectis is a planned subsidiary of Matricelf, established to develop and commercialize a medical solution for Parkinson's disease. Matricelf announced the spin-off in February 2026.
- What is the key technological approach of NeuroVectis?
- The company's key technological approach involves creating a living implant from patient-derived cells, extracellular matrix, hydrogel, and engineered neural tissue, designed to restore dopamine production and facilitate brain tissue repair.
- What stage of development is NeuroVectis currently in?
- NeuroVectis is currently in the R&D product stage and is categorized as Pre-Funding.